




JFW

 TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/734,589; confirmation 2607	
	Filing Date	12/15/2003	
	First Named Inventor	Govindan	
	Art Unit	1642	
	Examiner Name	Govindan	
Total Number of Pages in This Submission	2	Attorney Docket Number	328884


ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) ____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): credit card payment form (1 sheet) Information Disclosure Statement (2 pgs) 3 Foreign references; 4 non-patent literature documents
<div style="border: 1px solid black; padding: 5px;">Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm	FAEGRE & BENSON LLP		
Signature			
Printed Name	Richard A. Nakashiima		
Date	11/13/06	Reg. No.	42,023

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Signature			
Typed or printed name	Laura S. Mellblom	Date	11-3-06

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Attorney Docket No. 328884



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Govindan

Application No.: 10/734,589

Examiner: Brandon J. Fetterolf

Filed: 12/15/2003

Art Unit: 1642

For: IMMUNOCONJUGATES WITH AN
INTRACELLULARLY-CLEAVABLE
LINKAGE

INFORMATION DISCLOSURE STATEMENT
(37 C.F.R. §§ 1.97(b)(3) and 1.98)

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

The Examiner is requested to consider the references noted on the enclosed Form PTO/SB/08A (Substitute for form 1449A/PTO) during examination of the above-identified application. These references are submitted for the Examiner's consideration and are submitted pursuant to the duty of disclosure under 37 C.F.R. § 1.56. In submitting these references, no representation is made or implied that the references are or are not material to the examination of the application. The Examiner is encouraged to make his or her own determination of materiality.

The fee set forth in 37 CFR 1.17(p) has been submitted herewith. Should any additional fees and/or any underpayment of fee(s); credit any overpayments be deemed necessary, such fees may be charged to Deposit Account No. 06-0029.

11/07/2006 CNGUYEN 00000026 10734589

01 FC:1006

100.00 OP

Should the examiner have any questions concerning the relevance of any reference cited in this disclosure, please contact the undersigned attorney.


Dated: November 3, 2006

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'R. Nakashima', written over a horizontal line.

Richard A. Nakashima
Registration No. 42,023
Customer No. 35657

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/734,589; Confirmation 2607
Filing Date	12/15/2003
First Named Inventor	Govindan
Art Unit	1642
Examiner Name	Fetterolf
Attorney Docket Number	328884

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	6	KING, H. DALTON, et al., "Monoclonal Antibody Conjugates of Doxorubicin Prepared with Branched Linkers: A Novel Method for Increasing the Potency of Doxorubicin Immunoconjugates" Bioconjugate Chem., 1999, 10, 279-288 XP-000804254	
	7	CHARI, RAVI V. J., et al., "Immunoconjugates Containing Novel Maytansinoids: Promising Anticancer Drugs" 6175 Cancer Research 52 (1992) 1 January, No. 1, Balitomore, MD, US	
	8	HEINDEL, NED D., et al., "A Novel Heterobifunctional Linker for Formyl to Thiol Coupling" Bioconjugate Chem., 1991, 2, 427-430 XP-000983437	
	9	ROWLINSON-BUSZ, GAIL, et al., "Targeted delivery of Biologic and other Antineoplastic Agents" Current Opinion in Oncology 1992, 4:1142-1148 XP009027478	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.